Highlights of the latest heavy company rumors on Thursday
| Time: 08:42:00, January 9, 2020 |
: Termination of convertible bond
issuance Originally planned to raise 800 million yuan Rumors: Yingqu Technology
: It is expected that engraving machine products will also maintain steady growth in 2020 Rumors: Tianshun Wind Energy
: It is planned to invest 1.6 billion yuan to build Tianshun (shooting (Yang) Wind power offshore engineering and intelligent manufacturing project rumors: Anche detection
: shareholders Huarui Deyin and its concerted parties plan to reduce their holdings by no more than 6%. Rumors: Aier Ophthalmology
: Proposed purchase of Tianjin CTV and other 5 companies. 1.87 billion rumors: Wanrun Technology
: Shareholder Li Zhijiang and his concerted parties plan to reduce their holdings by no more than 3.32%. Rumors: Guizhou Bailing
: A proposed 200 million donation to care for people with diabetes will be completed in stages. Rumor: Wufang Optoelectronics
: Subsidiary plans to invest 120 million yuan in the construction of optical blue glass and microprism cold processing projects. Rumors: Joyson Electronics
: Revenue from related business with Tesla in 2019 is expected to be less than 2 billion yuan. Smaller rumors: Dalian Friendship
: Controlling shareholders intend to discount The actual controller of the transferred company's 28% shares will be changed to Wuhan State-owned Assets Supervision and Administration Commission. Rumors: Shengbang Co.
(300661) announced on the evening of January 8 that due to capital requirements, 1.98% of shareholders, Rongji Hong Kong, planned to adopt centralized bidding, block cross Holdings of shares of the company, the reduction of the number is expected to total no more than 100 million shares, that is not more than 0.97% of total share capital. The
total increase of Shengbang shares in
2019 reached 380%.
Rumors: Zhongzhu Medical
(600568) announced on the evening of January 8th that in order to recover the investment costs as soon as possible and reduce the risk of future uncertainty, the company signed an Equity Transfer Agreement with Guangzhou Yunjiang Island on the same day, with a total price of 1.11. 70 million yuan transfer of the company's 70% equity interest in Guangzhou Xin Taida. After the transfer is completed, the company will no longer hold the equity of Guangzhou New TEDA, and it is estimated that it will obtain a pre-tax income of about 58.13 million yuan.
Rumors: Yibai Pharmaceutical
(600594) announced on the evening of January 8 that the company ’s wholly-owned subsidiary Changan Pharmaceutical ’s existing production capacity has been unable to meet the company ’s main products, which are exclusively original first-class new drugs and third-generation platinum antitumor drugs for injection. Increasing market demand. In order to solve the bottleneck of development and to increase the company's production capacity of chemical drugs including anti-tumor drugs, Chang'an Pharmaceutical intends to invest in the construction of the "Meian Technology New City New Plant Construction Project" in Mei'an Science and Technology New City in Haikou. This project After completion, it will be engaged in the production and operation of related products. The total investment in fixed assets of this project is expected to be 603 million yuan.